ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
24 announcements with these filters
Caplin Point Laboratories concluded its 35th Annual General Meeting on September 25, 2026. Key business included adopting financial statements and approving the final dividend declaration.
Caplin Point Laboratories clarified that the recent increase in its stock's trading volume is market-driven. The company confirmed no undisclosed material information exists regarding this movement.
Caplin Point Laboratories Limited shared a weblink for its 35th AGM Notice and Annual Report for FY 2025-26. The communication targets shareholders with unregistered email addresses.
Caplin Point Laboratories Limited scheduled its 35th Annual General Meeting for September 25, 2026. Key agenda items include adopting financial statements and declaring a ₹4 final dividend.
Caplin Point Laboratories Limited submitted its Annual Report for FY 2025-26. The company's 35th Annual General Meeting is scheduled for September 25, 2026.
Caplin Point Laboratories has clarified that recent trading volume spikes are market-driven. The company confirms it has no undisclosed price-sensitive information.
Caplin Point Laboratories' subsidiary, Caplin One Labs, received GMP compliance certification from Colombia's INVIMA for its oncology drug manufacturing facility.
Caplin Point Laboratories completed an unannounced US FDA inspection at its subsidiary's facility. The company received 10 procedural observations and will respond within the stipulated timeframe.
Caplin reported strong Q1FY27 growth with 20% revenue and 19% PAT increase. Management is scaling capacity towards 15+ sterile lines while maintaining a debt-free balance sheet and high cash reserves.
Caplin Point delivers strong Q1FY27 growth driven by a 3x surge in US revenue. Management is aggressive on vertical integration and digitalization but faces near-term capacity constraints at key plants.
Caplin Point Laboratories re-appointed Dr. Sridhar Ganesan as Managing Director and appointed Mr. D. Muralidharan as Whole-Time Director. Both appointments are for two-year terms.
Caplin Point Laboratories fixed September 18, 2026, as the record date. This is for the 35th AGM and final dividend for FY 2025-26.
Caplin Point Laboratories Ltd reported revenue from operations of ₹610.4 Cr (+19.6% YoY) and net profit of ₹179.1 Cr (+18.8% YoY) for Q1 FY27.
Caplin Point Laboratories will hold a board meeting on August 12, 2026, to consider quarterly financial results and recommend a final dividend for FY 2025-26.
Caplin Point Laboratories Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details distributions across promoter and public categories.
Caplin Point Laboratories filed its Annual Secretarial Compliance Report for FY2026. The report confirms overall regulatory compliance with minor procedural delays waived by exchanges.
Caplin Point reported strong Q4 FY26 results with revenue doubling to INR 2,300cr and liquid assets tripling. Strategy focuses on massive injectable expansion and LATAM private market depth.
Caplin Point delivers a strong FY26 with revenue doubling over five years and a massive push into US injectables.
Caplin Point's subsidiary secured USFDA approval for Foscarnet Sodium Injection. The generic drug addresses a US market with approximately ₹142.5 Crore in annual sales.
Caplin Point Laboratories declared an interim dividend of ₹4 per share for FY 2025-26. The record date is May 30, with payment scheduled by June 13.
Caplin Point Laboratories Ltd reported revenue from operations of ₹600.2 Cr (+19.5% YoY) and net profit of ₹172.9 Cr (+19.0% YoY) for Q4 FY26.
Caplin Point Laboratories reported FY26 consolidated revenue of ₹2,187.19 Crore and PAT of ₹649.73 Crore. The Board also declared an interim dividend of ₹4 per share.
Caplin Point Laboratories Ltd has scheduled a Board Meeting on May 14, 2026. The board will consider audited financial results for FY2026 and a potential interim dividend for FY2025-26. The company's trading window remains closed until May 16, 2026.
Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received final USFDA approval for its Calcium Gluconate Injection USP. The product addresses acute symptomatic hypocalcemia and targets a US market with annual sales of approximately ₹674.5 Crore ($71 million). This approval strengthens the company's injectable portfolio in the regulated US market.